Functional heterogeneity and clinical implications of CD4+ T cell subtypes in high-grade serous ovarian carcinoma

doi:10.5306/wjco.v16.i5.104138

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

HTML

Figures (1-5)

Sum=16

May 24, 2025 (publication date) through May 19, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Clin Oncol. May 24, 2025; 16(5): 104138
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.104138

Full Size Figure Download Figure

Figure 5 Prognostic significance of CD4+ T cell subtypes in high-grade serous ovarian carcinoma. A: Overall survival analysis of CD4+ Treg subtypes in high-grade serous ovarian carcinoma; B: Disease-specific survival analysis of CD4+ Treg subtypes in high-grade serous ovarian carcinoma; C: Predictive performance of CD4+ Treg subtypes for immunotherapy response across multiple datasets; D: Association of CD4.Treg3 expression with overall survival in melanoma patients treated with PD-1 inhibitors; E: Impact of CD4.Treg3 expression on overall survival in melanoma patients treated with CTLA-4 inhibitors.

Citation: Zhang BL, Gao W, He L, Liu XT, Wang ZM, Tan L. Functional heterogeneity and clinical implications of CD4+ T cell subtypes in high-grade serous ovarian carcinoma. World J Clin Oncol 2025; 16(5): 104138
URL: https://www.wjgnet.com/2218-4333/full/v16/i5/104138.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i5.104138